Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models

Journal of Clinical Pharmacology

Volumn 41, Issue 11, 2001, Pages 1149-1179

  Venkatakrishnan, K ^a   Von Moltke, L L ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CALCIUM ANTAGONIST; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DIAZEPAM; ENZYME INDUCING AGENT; ENZYME INHIBITOR; GEPIRONE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; KETOCONAZOLE; NEFAZODONE; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TACROLIMUS; TRIAZOLAM; UNINDEXED DRUG;

BIOTRANSFORMATION; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; MATHEMATICAL MODEL; MOLECULAR GENETICS; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; PROTEIN EXPRESSION; REACTION ANALYSIS; REVIEW;

ALGORITHMS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 0034770465     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122012724     Document Type: Review

References (213)

1. Forty years of cytochrome P450
2. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
3. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics
4. The chemistry of cytochrome P450 reactions
5. Cytochrome P-450 1A1 expression in human small bowel: Interindividual variation and inhibition by ketoconazole
6. Characterization of human small intestinal cytochromes P-450
7. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
8. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles
9. Nicotine metabolism defect reduces smoking
10. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking
11. Monospecific antipeptide antibody to cytochrome P-450 2B6
12. Human cytochrome P4502B6. Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation
13. Further characterization of the expression in liver and catalytic activity of CYP2B6
14. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
15. Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages
16. CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants
17. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity
18. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes
19. The CYP2C subfamily
20. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
21. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations
22. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations
23. Sulfaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics
24. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines
25. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9
26. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance
27. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily
28. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes
29. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis
30. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
31. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
32. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism
33. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
34. Allelic, genotypic and phenotypic distributions of Smephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world
35. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19
36. Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA
37. Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C5
38. Nomenclature for human CYP2D6 alleles
39. The CYP2E1 subfamily
40. The CYP3A family
41. Genomic organization of the human CYP3A locus: Identification of a new, inducible CYP3A gene
42. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43
43. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450
44. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
45. Cytochrome P-450 3A4: Regulation and role in drug metabolism
46. Metabolism of drugs by cytochrome P450 3A isoforms: Implications for drug interactions in psychopharmacology
47. In vitro and in vivo drug interactions involving human CYP3A
48. Preparation and characterisation of microsomal fractions for studies on xenobiotic metabolism
49. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity
50. In vitro assessment of human cytochrome P450
51. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
52. Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes
53. In vitro approaches to predicting drug interactions in vivo
54. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P450
55. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes
56. Identification of the cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
57. Chemical, enzymatic, and human enantioselective S-oxygenation of cimetidine
58. N-oxygenation of clozapine by flavin-containing monooxygenase
59. Flavin-containing monooxygenase-mediated metabolism of psychoactive drugs by human brain microsomes
60. Cerebral flavin-containing monooxygenase-mediated metabolism of antidepressants in brain: Immunochemical properties and immunocytochemical localization
61. Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes
62. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities
63. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes
64. Flunitrazepam oxidative metabolism in human liver microsomes: Involvement of CYP2C19 and CYP3A4
65. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes
66. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes
67. Methanol solvent may cause increased apparent metabolic instability in in vitro assays
68. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
69. Nonspecific binding to microsomes: Impact on scaleup of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol
70. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low-affinity): Implications for interactions with enzyme-inducing drugs
71. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4
72. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
73. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
74. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: Role of CYP-2C9, -2C19, -2D6, and -3A
75. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants
76. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions
77. Triazolam substrate inhibition: Evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site
78. Cooperativity in oxidations catalyzed by cytochrome P450-3A4
79. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site
80. Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics
81. Elucidation of distinct ligand binding sites for cytochrome P450 3A4
82. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
83. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: An example of the metabolism of diazepam and its derivatives
84. Fitting curves to data using nonlinear regression: A practical and nonmathematical review
85. Application of the Akaike's Information Criterion in the evaluation of linear pharmacokinetic equations
86. Comparison of the Akaike Information Criterion, the Schwarz Criterion and the F test as guides to model selection
87. Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation
88. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects
89. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations
90. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: A study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs
91. Human cytochromes P450 mediating phenacetin O-deethylation in vitro: Validation of the high-affinity component as an index of CYP1A2 activity
92. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
93. The prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of the in vitro half-life approach and nonspecific binding to microsomes
94. m values: Implications for clinical correlation
95. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
96. Sigmoidal kinetics of CYP3A substrates: An approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in the rat
97. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
98. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations
99. Microsomal binding of amitriptyline: Effect on estimation of enzyme kinetic parameters in vitro
100. Nonspecific binding of drugs to human liver microsomes
101. A physiological approach to hepatic drug clearance
102. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
103. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics
104. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
105. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum
106. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
107. Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine
108. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man
109. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2
110. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
111. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
112. Activation of phenacetin O-deethylase activity by α-naphthoflavone in human liver microsomes
113. CYP2C9 is a principal low-affinity phenacetin O-deethylase: Fluvoxamine is not a specific CYP1A2 inhibitor
114. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
115. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
116. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
117. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin para-hydroxylation
118. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes
119. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants
120. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole
121. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen
122. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes
123. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: Inhibition by sulfaphenazole, omeprazole and ticlopidine
124. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
125. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
126. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies
127. Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism
128. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro
129. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
130. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: Contribution of several CYP isoforms
131. i values and impact of CYP3A5 expression
132. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research
133. The use of heterologously expressed drug metabolizing enzymes: State of the art and prospects for the future
134. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions
135. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6, and 3A4
136. Drug metabolism by Escherichia coli expressing human cytochromes P450
137. 5
138. Cytochrome P450 reconstitution systems
139. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily
140. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation
141. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches
142. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
143. Scaling drug biotransformation data cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism
144. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s
145. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: Studies on amitriptyline as a model substrate
146. Relative expression of cytochrome P450 isozymes in human liver and association with the metabolism of drugs and xenobiotics
147. Human N-demethylation of S-mephenytoin by cytochrome P450s 2C9 and 2B6
148. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8
149. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
150. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach
151. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes
152. Studies of flurbiprofen 4′-hydroxylation: Additional evidence suggesting the sole involvement of cytochrome P450 2C9
153. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes
154. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation
155. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
156. Bufuralol hydroxylation by Cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes
157. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6
158. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes
159. Omeprazole inhibits oxidative drug metabolism
160. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam
161. N-demethylation of amitriptyline in vitro: Role of cytochrome P450 3A (CYP3A) isoforms, and effect of metabolic inhibitors
162. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
163. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo
164. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine
165. Application of human liver microsomes in metabolism-based drug-drug interactions: In vitro-in vivo correlations and the Abbott laboratories experience
166. In vitro metabolic interaction studies: Experience of the Food and Drug Administration
167. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine
168. In vitro microsomal binding may bias chemical inhibition data
169. Effect of inhibitor depletion on inhibitor potency: Tight binding inhibition of CYP3A by clotrimazole
170. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo
171. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants
172. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole
173. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction
174. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates
175. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate dependent
176. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies
177. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part II
178. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro
179. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450
180. Differential inhibition of desipramine hydroxylation in vitro by the enantiomers of fluoxetine
181. Presystemic extraction: Mechanisms and consequences
182. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine
183. The CYP3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl
184. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences
185. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
186. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
187. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
188. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
189. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
190. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction
191. In vitro metabolism of trazodone by CYP3A: Inhibition by ketoconazole and human immunodeficiency viral protease inhibitors
192. Alprazolam-ritonavir interaction: Implications for product labeling
193. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam
194. Potential interaction between ritonavir and carbamazepine
195. Differential impairment of triazolam and zolpidem clearance by ritonavir
196. Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors
197. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine
198. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture
199. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors
200. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression
201. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
202. The Saint John's wort drug interaction: An in vitro analysis of p-glycoprotein (MDRI) induction due to chronic exposure
203. In vitro interaction of codeine and diclofenac
204. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlations
205. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide
206. Carbamazepine-valnoctamide interaction in epileptic patients: In vitro/in vivo correlation
207. Mechanism-based enzyme inactivators
208. Drug-mediated inactivation of cytochrome P450
209. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors
210. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: Comparison with ketoconazole
211. Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A
212. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation